Compare Enzyme (MLN) vs Obol (OBOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enzyme vs Obol — how do they compare? Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume), while Obol trades at Rp157.55 (market cap Rp30,1M, Rp51,72M 24h volume). The key difference: Enzyme is far larger — about 4.5× Obol's market cap, and Obol's supply is capped (161,3M / 500M OBOL (33%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Enzyme for 29 Days and Obol for 16 Days on average.
| MLN | OBOL | |
|---|---|---|
Market Cap | Rp134,13M | Rp30,1M |
Volume (24h) | Rp104,56M | Rp51,72M |
Circulating Supply | 3,3M MLN | 161,3M / 500M OBOL (33%) |
Typical Hold Time | 29 Days | 16 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enzyme (MLN) shows limited market activity with a modest market cap of Rp134,13M and circulating supply of 3,3jt tokens. The asset demonstrates relatively low volatility with an average hold time of 29 days, suggesting stable holder behavior. Trading volumes appear subdued across exchanges, indicating limited speculative interest. No significant protocol upgrades or ecosystem developments have been reported recently, though the project continues to operate its decentralized asset management platform.
Overall outlook remains cautious due to limited liquidity and trading activity. Key opportunities include potential ecosystem growth in decentralized finance asset management, while major risks include low market depth, regulatory uncertainty for DeFi protocols, and competition from larger DeFi platforms. The token's utility within its native protocol remains its primary value driver.
OBOL is a low-market-cap cryptocurrency with a market cap of Rp30.1 million and a circulating supply of 161.3 million tokens out of a maximum 500 million, indicating a 33% circulation rate. The asset shows limited trading activity with an average hold time of 16 days. No recent price or volume data is available, suggesting low liquidity. There are no major protocol updates or ecosystem developments reported recently.
The outlook for OBOL is highly speculative due to its small market size and lack of recent data. Key opportunities include potential growth if the project gains adoption, but major risks involve extreme volatility, low liquidity, and minimal market presence. Investors should exercise caution and conduct thorough research before considering this asset.
About Enzyme
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →About Obol
Obol develops vital technologies that enhance Ethereum's decentralization and security, currently protecting billions in staked ETH. Its Distributed Validators (DVs) offer better uptime, lower risk, and improved performance compared to traditional staking. Using the middleware Charon, DVs enable Ethereum validators to function across multiple operators and machines, featuring threshold signing and distributed key generation for added resilience. The Obol Collective, powered by the OBOL Token, includes the largest decentralized operator ecosystem with major players like Lido and Blockdaemon. The Obol Stack simplifies the deployment of Ethereum nodes and other decentralized infrastructures, advancing the Ethereum economy.
Read more on OBOL →
